Lynn Cunningham

Demonstration of the Efficacy and Safety of a Novel Substance P (NK1) Receptor Antagonist in Major Depression

Mark S. Kramer, Andrew Winokur, Jeffrey E. Kelsey et al. · Neuropsychopharmacology · 2003 · 258 citations

Psychiatry, Functional Selectivity, Medicine +14

Chronic hyperplastic sinusitis: Association of tissue eosinophilia with mRNA expression of granulocyte-macrophage colony-stimulating factor and interleukin-3

Daniel L. Hamilos, D LEUNG, Raymond P. Wood et al. · Journal of Allergy and Clinical Immunology · 1993 · 170 citations · Full text

Inflammation, Cytokine, Mrna Expression +10

A Comparison of Venlafaxine, Trazodone, and Placebo in Major Depression

Lynn Cunningham, Richard L. Borison, John Scott Carman et al. · Journal of Clinical Psychopharmacology · 1994 · 159 citations

Hamilton Rating Scale, Sleep, Psychoactive Drug +15

Exploring Extreme Programming in Context: An Industrial Case Study

Lucas Layman, Laurie Williams, Lynn Cunningham · Agile Development Conference · 2004 · 126 citations

Software Maintenance, Software Development Practice, Engineering +19

Sexual dysfunction associated with the treatment of depression: a placebo-controlled comparison of bupropion sustained release and sertraline treatment.

Charles Coleman, Lynn Cunningham, Vicki J. Foster et al. · Annals of Clinical Psychiatry · 1999 · 112 citations

Recurrent Major Depression, Placebo-controlled Comparison, Psychotropic Medication +19